TABLE 1

Baseline characteristics of per-protocol and intention-to-treat analysis sets

Per-protocol analysis set#ITT analysis set#
Usual careUrban TrainingAllUsual careUrban TrainingAll
Subjects n14588233148132280
Age years69±869±969±869±868±969±8
Female/male17 (12)/128 (88)12 (14)/76 (86)29 (12)/204 (88)18 (12)/130 (88)18 (14)/114 (86)36 (13)/244 (87)
Active smoker29 (20)20 (22)49 (21)30 (20)34 (26)64 (23)
Low socioeconomic status105 (73)64 (73)169 (73)107 (73)93 (71)200 (72)
Active worker16 (12)13 (15)29 (13)16 (11)19 (15)35 (13)
Dyspnoea mMRC grade (0–4)1±11±11±11±11±11±1
Post-bronchodilator FEV1 % pred58±1857±1658±1758±1856±1757±17
Post-bronchodilator FEV1/FVC ratio0.55±0.120.54±0.100.54±0.120.55±0.120.53±0.110.54±0.12
Airflow limitation+ mild/moderate/severe/very severe %10/55/30/58/57/31/49/55/31/510/54/30/69/51/32/810/53/31/6
GOLD 2017 assessment+ (A/B/C/D) %37/44/7/1235/52/0/1336/47/4/1336/44/7/1331/53/3/1334/48/5/13
Cardiovascular disease§88 (61)52 (60)140 (60)90 (61)81 (62)171 (61)
Diabetes mellitus§37 (26)25 (29)62 (27)38 (26)44 (34)82 (29)
Musculoskeletal diseases§55 (38)30 (34)85 (37)56 (38)51 (39)107 (38)
Charlson index2 (1–3)1 (1–2)2 (1–3)2 (1–3)2 (1–3)2 (1–3)
Inhaled corticosteroids (alone or in combination)81 (57)47 (55)128 (56)82 (57)68 (53)150 (55)
Long-acting bronchodilators (LAMA or LABA, alone or in combination)113 (80)73 (86)186 (82)116 (80)109 (85)225 (82)
Pulmonary rehabilitation at baseline6 (4)5 (6)11 (5)6 (4)6 (5)12 (4)
Pulmonary rehabilitation during follow-up6 (4)3 (3)9 (4)6 (4)6 (5)12 (4)

Data are presented as n, mean±sd, n (%) or median (interquartile range). ITT: intention-to-treat; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LAMA: long-acting muscarinic antagonist; LABA: long-acting β-agonist. #: some variables have missing values, as follows. Per-protocol analysis set: socioeconomic status (n=1) active worker (n=10), GOLD 2017 assessment (n=2), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); ITT analysis set: socioeconomic status (n=2), active worker (n=11), GOLD 2017 assessment (n=3), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); : UK National Statistics Socio-economic Classification III, IV or V; +: chronic obstructive pulmonary disease severity mild (FEV1 ≥80% pred), moderate (FEV1 50–79% pred), severe FEV1 (30–49% pred), very severe (FEV1 <30% pred) and A (low risk, low symptom burden), B (low risk, high symptom burden), C (high risk, low symptom burden), D (high risk, high symptom burden); §: cardiovascular disease (International Classification of Diseases, 10th revision (ICD-10) I00–I99), diabetes mellitus (ICD-10 E10–E14), musculoskeletal diseases (ICD-10 M00–M99).